Navigation Links
Conatus Pharmaceuticals Terminates Phase 2 Clinical Trial of CTS-1027
Date:10/25/2011

SAN DIEGO, Oct. 25, 2011 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the termination of its Phase 2 clinical trial of CTS-1027 in HCV patients.  This decision follows reports of laboratory abnormalities and adverse events in a subset of clinical trial participants.

The top priority of Conatus is patient safety, and the Company has made the decision to halt this study.  Conatus is conducting a thorough review of the available data to assess any future development of the compound.

Conatus Pharmaceuticals Inc. is a privately-held biopharmaceutical company engaged in the development of innovative human therapeutics in the areas of fibrotic disease and oncology. Conatus' lead drug candidate, emricasan (IDN-6556) is in development as a potential therapy for a variety of fibrotic diseases. Fibrotic diseases affect millions of people worldwide and can be caused by many different types of injuries. Conatus was founded by the executive management team of Idun Pharmaceuticals in July 2005 following the sale of Idun to Pfizer.  Conatus acquired the Idun subsidiary from Pfizer in 2010.  For additional information, please visit www.conatuspharma.com.


'/>"/>
SOURCE Conatus Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Oramed Pharmaceuticals Chosen to Present at the Diabetes Technology Meeting (October 27-29, 2011; San Francisco, CA)
2. Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2011 Financial Results Webcast and Conference Call
3. Syndax Pharmaceuticals to Present at Upcoming Fall Conferences
4. Avanir Pharmaceuticals to Present Data at MS-Focused ECTRIMS Annual Meeting
5. Regeneron Pharmaceuticals Announces Proposed Offering of Convertible Senior Notes due 2016
6. Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data to Be Presented at Upcoming Medical Meetings
7. Inspiration Biopharmaceuticals Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B
8. Elevation Pharmaceuticals Presents Positive Phase 2a Results in COPD Patients at the European Respiratory Society Annual Congress
9. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study
10. Anadys Pharmaceuticals Updates Its Presentation Date at the Stifel Nicolaus Healthcare Conference
11. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... GERMANTOWN, Md. , May 4, 2015   ... it will release first quarter 2015 financial results after ... will host a conference call that day at 5:30 ... general business update. The conference call may ... (International) and asking to join the "Intrexon Conference Call."  ...
(Date:5/1/2015)... MINNEAPOLIS, MN , May 1, 2015 /PRNewswire/ - ... company producing sustainable chemicals, today announced that it has priced ... common stock at a price of $9.00 per share, ... option to purchase up to an additional 585,000 shares ... Company will be $35.1 million.  The offering is expected to ...
(Date:5/1/2015)... ALBANY, N.Y. , May 1, 2015 ... today that William S. Marth , AMRI,s President ... of America Merrill Lynch 2015 Health Care Conference on ... A live audio webcast of the presentation can ... http://ir.amriglobal.com/events.cfm?CalendarID=2          The webcast will be ...
(Date:4/30/2015)... April 30, 2015   Tamir Biotechnology , a ... update on its Ebola antiviral therapy program. ... TMR004, is currently being evaluated and considered by a ... against Ebola. During the first quarter of 2015, the ... To Accelerate The Evaluation of Potential Treatments and Vaccines ...
Breaking Biology Technology:Intrexon to Announce First Quarter 2015 Financial Results on Monday, May 11, 2015 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3AMRI to Present at the Bank of America Merrill Lynch 2015 Health Care Conference 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4
... is my last article of the year, and I have talked ... New Year's resolution for this column is bring back more music ... that I simply have not gone to as many concerts this ... need to remedy!) , ,Looking over 2006, my focus has been ...
... you my predictions for the coming year and asked you ... predictions come true, 2007 is going to be a very ... of Singularity University , a community of technology futurists: ... Life becomes a credible next-generation platform for consumer and ...
... - The blood-brain barrier is a big problem when it ... University of Wisconsin-Madison believe they have found a way ... findings are the result of a collaborative study funded with a ... by UW-Madison professor of chemical and biological engineering Eric V. ...
Cached Biology Technology:2006: A great biotech financing year, unless you were going public! 22006: A great biotech financing year, unless you were going public! 32006: A great biotech financing year, unless you were going public! 42006: A great biotech financing year, unless you were going public! 5Reader predictions would make 2007 quite a year 2Reader predictions would make 2007 quite a year 3Reader predictions would make 2007 quite a year 4Reader predictions would make 2007 quite a year 5Stem cells may provide answer to blood-brain barrier 2
(Date:4/13/2015)... a leading cloud-based consumer engagement platform that provides trusted ... communities around health and wellness, announced today the launching ... The ... vehicle to receive validated health information from consumers. ... will allow higi,s trusted partners, on a user opt-in ...
(Date:4/2/2015)... April 2, 2015 In ... by far outperforms the strongest competitors, showing outstanding ... accuracy, the system is capable of a throughput ... proves up to be ten times faster than ... runner-up performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/1/2015)... 2015   Medisafe ™, the leading global medication ... iOS and Android smartphones and tablets, ... the platform to allow patients to track and correlate ... time, patients will be able to visualize in real-time ... biometrics, such as glucose levels and blood pressure. ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... A new study by top global fisheries experts presents ... The analysis of 61 species of "scombrids," which include ... include swordfish and marlins, classified seven as threatened with ... Red List of Threatened Species. University of Miami ...
... The Northwest Forest Plan enacted in 1993 was designed ... northern spotted owl, but researchers conclude in a new study ... carbon sequestration on public lands. When forest harvest levels ... after passage of this act, they became a significant carbon ...
... NEW YORK (July 22, 2011)A genetic study ... that the big-horned animals travel extensively across the ... to Wildlife Conservation Society researchers with the support ... Using a non-invasive technique that extracts DNA from ...
Cached Biology News:Double jeopardy: Tuna and billfish 2Northwest Forest Plan has unintended benefit - carbon sequestration 2World's largest sheep an international traveler 2World's largest sheep an international traveler 3
... ,Schistosomal glutathione-S-transferase (GST) is commonly ... proteins in E. coli (1). The GSTTag ... production and in some cases the solubility ... a soluble, properly folded form, GSTTag fusion ...
... used as a fusion partner when expressing ... sequence has been reported to enhance the ... of its fusion partners. When expressed in ... proteins can be purified with immobilized glutathione. ...
... with Medium High quality ready-to-use cryopreserved neural ... medium for growth and lineage commitment. Just ... from E18 fetal rat brain in the ... of in vitro stem/progenitor cells, neurons, astrocytes ...
... The ELx50 is a fast and versatile ... with our patented Dual-ActionTM 16-channel manifold. This ... the dispense and aspiration manifolds for overfill ... and 384-well formats. The problem of fitting ...
Biology Products: